Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.

@article{Napolitano2014OptimalDO,
  title={Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.},
  author={M. Napolitano and Giorgia Saccullo and A. Malato and D. Sprini and W. Ageno and Davide Imberti and D. Mascheroni and E. Bucherini and Pina Gallucci and A. D’Alessio and T. Prantera and P. Spadaro and S. Rotondo and P. di Micco and V. Oriana and Oreste Urbano and F. Recchia and A. Ghirarduzzi and L. Lo Coco and S. Mancuso and A. Casuccio and G. B. Rini and S. Siragusa},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 32},
  pages={
          3607-12
        }
}
  • M. Napolitano, Giorgia Saccullo, +20 authors S. Siragusa
  • Published 2014
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • PURPOSE We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs. PATIENTS AND METHODS Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to… CONTINUE READING
    62 Citations
    Should anticoagulation therapy be withheld in patients with active cancer after 6 months of low-molecular weight heparin?
    • 1
    Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
    • A. Young, A. Marshall, +15 authors M. Levine
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2018
    • 442
    • PDF
    Quality of Life in Patients With Cancer Under Prolonged Anticoagulation for High-Risk Deep Vein Thrombosis: a Long-Term Follow-Up
    • 1
    Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer
    • 3

    References

    SHOWING 1-10 OF 29 REFERENCES
    Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    • 1,866
    • PDF
    Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.
    • 520
    • Highly Influential
    The effect of low molecular weight heparin on survival in patients with advanced malignancy.
    • 555
    Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism
    • 487
    Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
    • 618
    D-dimer testing to determine the duration of anticoagulation therapy.
    • 432